Showing items 1 - 2 of 2

Your selections:

Exploring locoregional treatment reporting in neoadjuvant systemic breast cancer treatment studies: A systematic review

- Jiang, Michael, Avery, Kerry, MacKenzie, Mairead, Meyn, Anne, Poulakaki, Fiorita, Richardson, Andrea L., Sepulveda, Karla, Spillane, Andrew, Thompson, Alastair M., Werutsky, Gustavo, Wright, Jean L., Zdenkowski, Nicholas, Ahmed, Rosina, Cowan, Katherine, McIntosh, SA, Potter, S, de Boniface, Jana, Chatterjee, Sanjoy, Dodwell, David, Dubsky, Peter, Finestone, Sandy, Iwata, Hiroji, Lee, Han-Byoel

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

- Saura, Christina, Oliveira, Mafalda, Hlauschek, Dominik, Zardavas, Dimitrios, Jallitsch-Halper, Anita, de la Peña, Lorena, Nuciforo, Paolo, Ballestrero, Alberto, Dubsky, Peter, Lombard, Janine M., Vuylsteke, Peter, Castaneda, Carlos A., Colleoni, Marco, Santos Borges, Giuliarno, Ciruelos, Eva, Fornier, Monica, Boer, Katalin, Bardia, Aditya, Wilson, Timothy R., Stout, Thomas J.

  • 1
  • Disclaimer
  • Privacy
  • Copyright
  • Contact
  • Deposit